• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Edgewise Therapeutics Inc.

    11/14/24 4:14:38 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EWTX alert in real time by email
    SC 13G 1 tm2426483d2_sc13g.htm SC 13G

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    Edgewise Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

      28036F105  
      (CUSIP Number)  
         
      September 30, 2024  
      (Date of Event which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)

     

      ¨ Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

      

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.  28036F105

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5 

    SOLE VOTING POWER

     

    5,840,059

    6 

    SHARED VOTING POWER

     

    -0-

    7 

    SOLE DISPOSITIVE POWER

     

    5,840,059

    8 

    SHARED DISPOSITIVE POWER

     

    -0-

    9

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,840,059

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.2% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IA, PN

     

      (1) Based upon 93,772,288 shares of common stock (“Common Stock”) of Edgewise Therapeutics, Inc. (the “Issuer”) outstanding as of July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 8, 2024.

     

    Page 2 of 10 Pages

     

     

    CUSIP No.  28036F105

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors (GP) LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5 

    SOLE VOTING POWER

     

    5,840,059

    6 

    SHARED VOTING POWER

     

    -0-

    7 

    SOLE DISPOSITIVE POWER

     

    5,840,059

    8 

    SHARED DISPOSITIVE POWER

     

    -0-

    9

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,840,059

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.2% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    HC, OO

     

    (1)Based upon 93,772,288 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

     

    Page 3 of 10 Pages

     

                     

    CUSIP No.  28036F105

     

    1

    NAMES OF REPORTING PERSONS

     

    Felix J. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 

    (a) ¨

    (b) ¨

    3 SEC USE ONLY 
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5 

    SOLE VOTING POWER

     

    5,840,059

    6 

    SHARED VOTING POWER

     

    -0-

    7 

    SOLE DISPOSITIVE POWER

     

    5,840,059

    8 

    SHARED DISPOSITIVE POWER

     

    -0-

    9

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,840,059

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.2% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

     

    (1)Based upon 93,772,288 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

     

    Page 4 of 10 Pages

     

     

    CUSIP No.  28036F105

     

    1

    NAMES OF REPORTING PERSONS

     

    Julian C. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5 

    SOLE VOTING POWER

     

    5,840,059

    6 

    SHARED VOTING POWER

     

    -0-

    7 

    SOLE DISPOSITIVE POWER

     

    5,840,059

    8 

    SHARED DISPOSITIVE POWER

     

    -0-

    9

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,840,059

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (See Instructions)

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.2% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

     

    (1)Based upon 93,772,288 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 8, 2024.

     

    Page 5 of 10 Pages

     

     

    Schedule 13G

     

    Item 1(a) Name of Issuer:
       
      Edgewise Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:
       
      1715 38th Street
       
      Boulder, Colorado 80301

     

    Item 2(a) Name of Person Filing:
       
      This Schedule 13G is being filed jointly by the Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Felix J. Baker and Julian C. Baker (collectively, the “Reporting Persons”).

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:
       
      The business address of each of the Reporting Persons is:
       
      c/o Baker Bros. Advisors LP
       
      860 Washington Street, 3rd Floor
       
      New York, NY 10014
       
      (212) 339-5690

     

    Item 2(c) Citizenship:
       
      The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:
       
      Common Stock, $0.0001 par value per share (“Common Stock”)

     

    Item 2(e) CUSIP Number:
       
      28036F105

     

    Page 6 of 10 Pages

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b)¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

    (e)x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    (g)x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

    (j)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons.

     

    The information set forth below is based on 93,772,288 shares of Common Stock outstanding as of July 31, 2024 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

    Page 7 of 10 Pages

     

     

    Name  Number of shares of
    Common
    Stock we own or have the
    right to acquire within 60
    days
       Percent of
    Class
    Outstanding
     
    667, L.P.   415,892    0.4%
    Baker Brothers Life Sciences, L.P.   5,424,167    5.8%
    Total   5,840,059    6.2%

     

    Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. N/A

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Page 8 of 10 Pages

     

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 9 of 10 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    November 14, 2024

     

      BAKER BROS. ADVISORS LP
       
      By: Baker Bros. Advisors (GP) LLC, its general partner
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
        Title: President
         
      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name:    Scott L. Lessing
        Title: President
         
        /s/ Julian C. Baker
        Julian C. Baker
         
        /s/ Felix J. Baker
        Felix J. Baker

     

    Page 10 of 10 Pages

     

     

     

     

    Get the next $EWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EWTX

    DatePrice TargetRatingAnalyst
    4/30/2025$41.00Buy
    Guggenheim
    4/2/2025$14.00Sector Outperform → Sector Perform
    Scotiabank
    3/7/2025$50.00Sector Outperform
    Scotiabank
    1/22/2025$30.00Hold
    Stifel
    11/22/2024$45.00Outperform
    Evercore ISI
    3/7/2024$48.00Overweight
    Piper Sandler
    5/1/2023Buy
    Truist
    8/25/2022$5.00Neutral → Sell
    Goldman
    More analyst ratings

    $EWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – –  On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo., May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today reported financial results

      5/8/25 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025, subject to the satisfaction of customary closing conditions. The deal

      4/2/25 6:22:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

      – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from th

      4/2/25 6:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Edgewise Therapeutics with a new price target

      Guggenheim initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $41.00

      4/30/25 8:12:14 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics downgraded by Scotiabank with a new price target

      Scotiabank downgraded Edgewise Therapeutics from Sector Outperform to Sector Perform and set a new price target of $14.00

      4/2/25 11:46:29 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Edgewise Therapeutics with a new price target

      Scotiabank initiated coverage of Edgewise Therapeutics with a rating of Sector Outperform and set a new price target of $50.00

      3/7/25 8:04:46 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EWTX
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 6:22:11 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

      SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:31:39 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Edgewise Therapeutics Inc.

      SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)

      11/14/24 4:14:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos

      9/11/22 5:00:00 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

      – EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month

      6/20/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

      - Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi

      6/16/22 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

      Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin

      5/7/24 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

      – President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos

      3/6/23 8:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer

      – Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer (CMO) at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President o

      12/20/22 9:00:00 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EWTX
    SEC Filings

    See more

    $EWTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Edgewise Therapeutics Inc.

      10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:05:22 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      5/8/25 8:00:45 AM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Edgewise Therapeutics Inc.

      DEFA14A - Edgewise Therapeutics, Inc. (0001710072) (Filer)

      4/29/25 4:16:25 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:42:30 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      4/4/25 7:33:31 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thompson Peter A. bought $4,999,995 worth of shares (454,545 units at $11.00) (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      1/25/24 4:32:07 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Russell Alan J converted options into 5,209 shares and sold $25,520 worth of shares (1,551 units at $16.45), increasing direct ownership by 25% to 18,521 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:58 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Moore John R converted options into 5,209 shares and sold $31,757 worth of shares (1,930 units at $16.45), increasing direct ownership by 101% to 6,531 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:38 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Koch Kevin converted options into 10,417 shares and sold $70,358 worth of shares (4,276 units at $16.45), increasing direct ownership by 42% to 20,619 units (SEC Form 4)

      4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

      5/7/25 9:10:20 PM ET
      $EWTX
      Biotechnology: Pharmaceutical Preparations
      Health Care